# Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

> **NCT01617681** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 127 (actual)

## Conditions studied

- Pediatric Hypertension With or Without CKD

## Interventions

- **DRUG:** VAL489
- **DRUG:** VAL489 matching placebo

## Key facts

- **NCT ID:** NCT01617681
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-08
- **Primary completion:** 2017-01-24
- **Final completion:** 2017-01-24
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2017-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617681, "Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01617681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*